Description
A PAI-1 inhibitor (IC50 = 6.95 µM); inhibits formation of a complex consisting of tPA, PAI-1, and GFP on VECsin vitro, prolonging the time that tPA is retained on VECs; decreases blood clot weight in a rat model of arteriovenous shunt thrombosis when used at doses of 10 and 50 mg/kg; increases the time to primary occlusion in a ferric chloride-treated carotid artery thrombosis model in rats when used at doses of 1 and 3 mg/kg; increases the time to primary occlusion in a cynomolgus monkey model of photochemical-induced arterial thrombosis when used at a dose of 10 mg/kg; does not affect platelet activity, activated partial thromboplastin time, prothrombin time, or prolong bleeding time
Formal name: 5-chloro-2-[[2-[2-[4-(diphenylmethyl)-1-piperazinyl]-2-oxoethoxy]acetyl]amino]-benzoic acid, monosodium salt
Synonyms:
Molecular weight: 544
CAS: 1103926-82-4
Purity: ≥95%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Blood Coagulation Factors||Research Area|Cardiovascular System|Blood|Acute Phase Reactants||Research Area|Cardiovascular System|Blood|Thrombosis||Research Area|Cardiovascular System|Vasculature|Endothelium